Ketelina Bergel

Ms. Ketelina Bergel


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RTRoman P. Terekhov
Roman P. Terekhov
ASArtem Aleksandrovich Svotin
Artem Aleksandrovich Svotin
Denis Igorevich PankovDenis Igorevich Pankov
Denis Igorevich Pankov
MKMaria D. Korochkina
Maria D. Korochkina
EKElizaveta A. Krivosheeva
Elizaveta A. Krivosheeva
ISIrina Selivanova
Irina Selivanova
Background: Obesity is a global epidemic and a complex chronic disease affecting more than one billion patients, leading to severe health issues like diabetes, heart disease, and cancer. While lifestyle changes are the first-line treatment, they are often insufficient. Current medications may cause severe side effects, including muscle loss and vision problems. Objectives: This systematic review aims to generalize and evaluate data from preclinical studies on the effect of flavonoid dihydroquercetin (DHQ) on weight loss in experimental animals compared with placebo-treated animals. Methods: This systematic review was conducted in accordance with the PRISMA guidelines. The protocol was registered in the PROSPERO database in August 2025 (CRD420251129793). Risk of bias (RoB) was assessed by using SYRCLE’s tool. Results: In total, eight studies included in the systematic review involved 175 animals (14 treatment groups and 9 control groups). Calculation of correlations between the reported effect on weight change and initial weight showed a strong association between these rates (R −0.9883). The intensity of DHQ effect depended on the condition: There were strong negative correlations between DHQ dose and the observed effect in diabetes mellitus (R −0.9056), hepatic lipid dysmetabolism (R −0.9339), and hepatic fibrosis (R −0.9025) in mice and rats’ data together. Conclusions: Intake of DHQ in the course of one month and three months resulted in a decrease in animals’ weight by 5.24% ± 1.95% and 18.29% ± 1.96% (p < 0.0001), respectively. Taken together, our results suggest the rationality for further research of DHQ as an anorexigenic agent, focusing on the stereochemistry of this flavonoid and its bioavailability optimization.

20 April 2026 in Problems of Biological, Medical and Pharmaceutical Chemistry
Verified
Journal Article
Closed access
RTRoman P. Terekhov
Roman P. Terekhov
ASArtem Aleksandrovich Svotin
Artem Aleksandrovich Svotin
Denis Igorevich PankovDenis Igorevich Pankov
Denis Igorevich Pankov
MKMaria D. Korochkina
Maria D. Korochkina
EKE. Krivosheeva
E. Krivosheeva
ISIrina Selivanova
Irina Selivanova
Obesity is a distinct disease that leads to severe health issues like diabetes, heart disease, and cancer. The spread of this pathology can be compared to an epidemic. The search for medications for weight control remains an actual challenge for pharmaceutical and medical sciences. In particular, studying the anorexigenic effect of the flavanol dihydroquercetin (DHQ) is of special interest. Bibliographic databases contain a lot of studies reporting the dynamics of weight changes on the background of taking this flavonoid, and recent studies have shown that DHQ promotes weight loss. Therefore, the aim of this article is to assess the data of experimental studies on the effect of DHQ on the body weight of experimental animal model compared to control groups. The study results demonstrate statistically significant weight loss in mice and rats with various pathologies within the first month of DHQ administration. The biological effect of the flavonoid under the described conditions was comparable to the effect of GLP-1 receptor agonists. Thus, if the results of fundamental research are successfully translated into clinical practice, the use of this flavonoid will make it possible to reduce therapeutic doses of standard medications and will provide administration for patients requiring mild pharmacological intervention. This could improve the life quality of 483 million patients worldwide. Realization of this strategy would reduce the procurement and production of GLP-1 receptor agonists, which, given the high cost of treatment, would reduce the economic burden on the healthcare system. A systematic review identified a number of challenges for pharmaceutical science that require solutions for the successful development of a drug based on DHQ. In particular, future research should focus on studying the influence of flavanonol stereochemistry on its biological effect, as well as on identifying modifications with improved bio-availability and optimal dosage form.

Verified
Journal Article
Open access
PDF file
RTRoman P. Terekhov
Roman P. Terekhov
ATAmir Taldaev
Amir Taldaev
ASArtem Aleksandrovich Svotin
Artem Aleksandrovich Svotin
Denis Igorevich PankovDenis Igorevich Pankov
Denis Igorevich Pankov
ESEvgenia Sukhova
Evgenia Sukhova
ISIrina Selivanova
Irina Selivanova
Dihydroquercetin (DHQ) is a promising object for the development of a treatment for patients with obesity and prediabetes requiring a moderate therapeutic effect. This paper reports a clinical case of DHQ application in a 30-year-old Caucasian male and proposes a molecular mechanism of its anti-obesity effect. DHQ was administrated as a dietary supplement at a dose of 100–200 mg/day during 3 months with treatment interruption for 1 month. The data collected one month before the treatment were used as a control. The molecular aspects were studied via molecular docking with β3-adrenoceptor (ADRB3, PDB ID: 9IJE) and peroxisome proliferator-activated receptor γ (PPARG, PDB ID: 2ZNO) and molecular dynamic simulation under conditions mimicking a human cellular environment. A pronounced weight decrease up to 0.73 kg/week was observed during DHQ administration. The highest affinity to ADRB3 was observed for the non-ionized H2aH3e-conformation of 2S,3R-DHQ (–8.846 kcal/mol). Molecules with 2S-configuration demonstrate 0.332 kcal/mol higher affinity to PPARG compared to 2R-stereoisomers. The intermolecular complex with cis-DHQ demonstrated higher stability in molecular dynamics simulation. The insights gained from this study may contribute to our understanding of flavonoids not merely as antioxidants but also as active ingredients that selectively interact with receptors. If future investigations confirm these results, they may serve as a foundation for developing a new class of anti-obesity remedies that act via ADRB3.